Evidence map›Paper›PMID 28722352›Full record

ArticleAging cell2017

Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung disease.

Chunsun Jiang, Gang Liu, Tracy Luckhardt, Veena Antony, Yong Zhou, A Brent Carter, Victor J Thannickal, Rui-Ming Liu

Open access · goldAbstract read
In one paragraph

Article in Aging cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 229 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. SERPINE1 in ARDS: an emerging regulator of inflammation-coagulation-fibrinolysis crosstalk.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  6. Article
  7. Article
  8. Integrative Approaches to Treating Cellular Senescence in Kidney Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chunsun JiangDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Gang LiuDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Tracy LuckhardtDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Veena AntonyDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Yong ZhouDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
A Brent CarterDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Victor J ThannickalDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Rui-Ming LiuDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Alabama at Birmingham · US

Funding

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung DiseaseP01HL114470 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THANNICKAL, VICTOR J. · 2013 to 2022
$17.8M
Lung Macrophage Metabolic Reprogramming in Asbestos-Induced ToxicityR01ES015981 · NIEHS · UNIVERSITY OF IOWA · PI CARTER, A BRENT · 2007 to 2022
$5.5M
Program on cellular metabolism and lung fibrosisR35HL135830 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, GANG · 2017 to 2023
$5.2M
Myofibroblast Senescence in Pulmonary FibrosisR01AG046210 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THANNICKAL, VICTOR J. · 2014 to 2018
$1.6M
The Role of Biomechanical Signaling in Lung FibrosisR01HL124076 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHOU, YONG · 2015 to 2018
$1.5M
PAI-1 and aging-related susceptibility to lung fibrosisR56HL131054 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUI-MING · 2016 to 2016
$438k
Sirtuins in Lung Aging and FibrosisI01BX003056 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI THANNICKAL, VICTOR J. · 2016 to 2025
–
BLRD VA I01 BX003056NHLBI NIH HHS P01 HL114470NHLBI NIH HHS R01 HL124076NHLBI NIH HHS R35 HL135830NHLBI NIH HHS R56 HL131054NIA NIH HHS R01 AG046210NIEHS NIH HHS R01 ES015981
6 · The paper itself

Abstract

Senescence of alveolar type 2 (ATII) cells, progenitors of the alveolar epithelium, is implicated in the pathogeneses of idiopathic pulmonary fibrosis (IPF), an aging-related progressive fatal lung disorder with unknown etiology. The mechanism underlying ATII cell senescence in fibrotic lung diseases, however, remains poorly understood. In this study, we report that ATII cells in IPF lungs express higher levels of serpine 1, also known as plasminogen activator inhibitor 1 (PAI-1), and cell senescence markers p21 and p16, compared to ATII cells in control lungs. Silencing PAI-1 or inhibition of PAI-1 activity in cultured rat ATII (L2) cells leads to decreases in p53 serine 18 phosphorylation (p53

Indexed as

AgingAlveolar Epithelial CellsAnimalsBleomycinCell LineCellular SenescenceCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21Disease Models, AnimalDoxorubicinGene Expression RegulationIdiopathic Pulmonary FibrosisLungMaleMiceMice, KnockoutBleomycinCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21DoxorubicinPlasminogen Activator Inhibitor 1Retinoblastoma ProteinRNA, Small InterferingTumor Suppressor Protein p53aginglung fibrosisp53serpin 1type 2 alveolar epithelial cell senescence

Identifiers

PMID28722352
PMCPMC5595683
OpenAlexW2738609590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.